Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mohamed Altai

Showing results (31-40 of 62) with videos related to

Pageof 7
Sort By:
International Journal of Oncology|December 2, 2014
Imaging of CAIX-expressing xenografts in vivo using 99mTc-HEHEHE-ZCAIX:1 affibody moleculeHadis Honarvar, Javad Garousi, Elin Gunneriusson, et al.
Scientific Reports|June 27, 2018
Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapyAnzhelika Vorobyeva, Kristina Westerlund, Bogdan Mitran, et al.
Scientific Reports|November 28, 2020
Evaluation of an antibody-PNA conjugate as a clearing agent for antibody-based PNA-mediated radionuclide pretargetingAnders Myrhammar, Anzhelika Vorobyeva, Kristina Westerlund, et al.
Journal of Medicinal Chemistry|May 23, 2013
HAHAHA, HEHEHE, HIHIHI, or HKHKHK: influence of position and composition of histidine containing tags on biodistribution of [(99m)Tc(CO)3](+)-labeled affibody moleculesCamilla Hofström, Mohamed Altai, Hadis Honarvar, et al.
Contrast Media & Molecular Imaging|July 7, 2018
Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant TumorsAnzhelika Vorobyeva, Olga Bragina, Mohamed Altai, et al.
Cells|October 14, 2018
Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic ConstructsMohamed Altai, Charles Dahlsson Leitao, Sara S Rinne, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 11, 2012
Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenograftsJennie Malmberg, Anna Perols, Zohreh Varasteh, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|May 15, 2019
Selection of the optimal macrocyclic chelators for labeling with <sup>111</sup>In and <sup>68</sup>Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6Emma von Witting, Javad Garousi, Sarah Lindbo, et al.
Cancers|July 24, 2021
A Conjugation Strategy to Modulate Antigen Binding and FcRn Interaction Leads to Improved Tumor Targeting and Radioimmunotherapy Efficacy with an Antibody Targeting Prostate-Specific AntigenOskar Vilhelmsson Timmermand, Anders Örbom, Mohamed Altai, et al.
International Journal of Molecular Sciences|May 13, 2020
Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPin Ec1Anzhelika Vorobyeva, Elena Konovalova, Tianqi Xu, et al.
Pageof 7

Showing results (31-40 of 62) with videos related to

Sort By:
Pageof 7
International Journal of Oncology|December 2, 2014
Imaging of CAIX-expressing xenografts in vivo using 99mTc-HEHEHE-ZCAIX:1 affibody moleculeHadis Honarvar, Javad Garousi, Elin Gunneriusson, et al.
Scientific Reports|June 27, 2018
Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapyAnzhelika Vorobyeva, Kristina Westerlund, Bogdan Mitran, et al.
Scientific Reports|November 28, 2020
Evaluation of an antibody-PNA conjugate as a clearing agent for antibody-based PNA-mediated radionuclide pretargetingAnders Myrhammar, Anzhelika Vorobyeva, Kristina Westerlund, et al.
Journal of Medicinal Chemistry|May 23, 2013
HAHAHA, HEHEHE, HIHIHI, or HKHKHK: influence of position and composition of histidine containing tags on biodistribution of [(99m)Tc(CO)3](+)-labeled affibody moleculesCamilla Hofström, Mohamed Altai, Hadis Honarvar, et al.
Contrast Media & Molecular Imaging|July 7, 2018
Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant TumorsAnzhelika Vorobyeva, Olga Bragina, Mohamed Altai, et al.
Cells|October 14, 2018
Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic ConstructsMohamed Altai, Charles Dahlsson Leitao, Sara S Rinne, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 11, 2012
Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenograftsJennie Malmberg, Anna Perols, Zohreh Varasteh, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|May 15, 2019
Selection of the optimal macrocyclic chelators for labeling with <sup>111</sup>In and <sup>68</sup>Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6Emma von Witting, Javad Garousi, Sarah Lindbo, et al.
Cancers|July 24, 2021
A Conjugation Strategy to Modulate Antigen Binding and FcRn Interaction Leads to Improved Tumor Targeting and Radioimmunotherapy Efficacy with an Antibody Targeting Prostate-Specific AntigenOskar Vilhelmsson Timmermand, Anders Örbom, Mohamed Altai, et al.
International Journal of Molecular Sciences|May 13, 2020
Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPin Ec1Anzhelika Vorobyeva, Elena Konovalova, Tianqi Xu, et al.
Pageof 7